Can a Triple-Drug combo tame a rare heart disease?
NCT ID NCT07743957
First seen Aug 04, 2026 · Last updated Aug 14, 2026 · Updated 3 times
Summary
This phase II trial is testing whether a combination of selinexor, daratumumab, and dexamethasone (called XDd) can help people with advanced light-chain cardiac amyloidosis, a condition where abnormal proteins build up in the heart. The study aims to see if the regimen can achieve a complete blood response and improve heart and organ function, as well as quality of life. Participants receive the drugs weekly or less often over several cycles, and the trial will track outcomes like survival and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- A combination of three drugs: selinexor (taken by mouth weekly), daratumumab (given as an injection under the skin), and dexamethasone (a steroid taken by mouth weekly).
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced light-chain cardiac amyloidosis, potentially improving blood and heart responses and extending survival.
- What could go wrong
- This is a phase II trial with a relatively small number of participants, so results may not be conclusive. The drugs can cause side effects, and the regimen may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIGHT-CHAIN CARDIAC AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.